Articles

Biotech drug developer Sagimet Biosciences is taking another shot at going public, according to a filing with the SEC late Friday.

The collapse of an elevated section of Interstate 95 in Philadelphia sparked fears of a monthslong traffic snarl.

Uber shares have been on a tear this year, but Barclays analyst Ross Sandler sees ample room for the dominant ride-hailing name to continue cruising.

Total bank lending rose by $22.8 billion to $12.1 trillion in the week ending June 14, the Federal Reserve reported Friday.

Zuckerberg has caught Musk's attention with his plan for a Twitter rival, and the two tech heavyweights have challenged each other to a cage match.

Transportation Secretary Pete Buttigieg warns Friday of the potential for 5G flight delays for airlines who haven't upgraded altimeters by a July 1 deadline.

Julius Ivancsits stepped down as Hexo CFO as Tilray closed a deal to buy the company on Thursday.

Money and investing stories popular with MarketWatch readers over the past week.

New restrictions and legal uncertainties pit doctors against patients and put anyone who can get pregnant at risk, researchers say.

Wells Fargo analysts say investors have failed to ask a key question: What if Molson Coors' gains go away?

Trading in U.S. stock options has surged in 2023 as retail and institutional traders have harnessed bullish call options to chase a runaway rally in U.S. stocks, market strategists told MarketWatch.

Fed Vice Chair Michael Barr is looking at "different ways an institution can die" by pursuing "reverse stress tests" for banks as pundits keep an eye out for trouble in the sector.